Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Core Insights - Nexalin Technology, Inc. announced a peer-reviewed clinical study demonstrating that its Deep Intracranial Frequency Stimulation (DIFS™) technology leads to significant improvements in attention and cognitive performance in adults with ADHD, supported by objective brain imaging data [1][9] Group 1: Study Overview - The study was a randomized, double-blind, sham-controlled trial involving 56 adults with ADHD who underwent four weeks of Nexalin's non-invasive neurostimulation [2] - Participants receiving active treatment showed a 10.1-point average improvement on the Adult ADHD Self-Report Scale, compared to a 5.5-point improvement in the sham group, indicating a statistically significant difference (p < 0.001) [2] Group 2: Brain Imaging and Functionality - The study utilized magnetoencephalography (MEG) to assess real-time neural activity, revealing that Nexalin's DIFS™ technology reduced excessive gamma-frequency brain activity, which is often linked to ADHD symptoms [3][4] - Post-treatment, there was a normalization of communication between key brain networks involved in attention, memory, and cognitive control, suggesting improved coordination across critical brain regions [5] Group 3: Clinical Outcomes and Safety - Adults receiving active stimulation experienced significant improvements in concentration, reductions in ADHD symptoms, and enhancements in mood and sleep quality, with a safety profile comparable to sham stimulation [6] - The treatment was well tolerated, with no serious adverse events reported, reinforcing the safety of Nexalin's approach [6] Group 4: Broader Implications - The findings indicate a shift in understanding mental health conditions as disorders of brain network regulation rather than isolated chemical imbalances, positioning Nexalin's DIFS™ technology as a drug-free approach to neuromodulation [9] - Nexalin's neurostimulation devices are approved in multiple international markets, and the company continues to advance research across various neurological and psychiatric conditions [10]